Restarting Semaglutide Early After Stomach Surgery in Teens With Severe Obesity
Compares restarting semaglutide 2 weeks after sleeve gastrectomy with standard care in youth.
Key facts
- Who runs it
- Children's Hospital Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Nov 2033
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Semaglutide 2.4 mg
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people aged 12 to 18 with severe obesity who take semaglutide 2.4 mg weekly and are having sleeve gastrectomy surgery at Children's Hospital Los Angeles.
- Age
- 12 to 18 years
- Sex
- All sexes can join.
- Disease stage
- Severe obesity (BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile). Tanner stage 3 or higher.
- Earlier treatment
- Must be taking semaglutide 2.4 mg weekly as part of routine care before surgery. The summary says for at least 3 months.
Main reasons for not taking part
- Previous diagnosis of type 1 diabetes
- Taking medicines that affect body weight, such as prednisone
- Syndromes or diseases that may affect recovery after surgery, such as Cushing syndrome, Down syndrome or Prader Willi Syndrome
- Other serious medical conditions that need frequent hospital stays or make restarting semaglutide early unsafe
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ages 12 to 18 years
- Tanner stage 3 or higher
- severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)
- currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
- be willing to have blood collected before and after surgical procedure at defined points
- be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver
- be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure
Who cannot take part
- have a previous diagnosis of type 1 diabetes
- taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)
- have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)
- have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities
- refuse to comply with eligibility criteria
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Where in United States
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Alaina Alaina Vidmar, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.
The 2 groups in the trial
- Standard CareNo study treatment, for comparison
Standard of care following bariatric surgery. No Reinitiation of obesity optimizing medications.
- Early reinitiationTreatment being tested
Early Reinitiation of semaglutide at 2 weeks after bariatric surgery per standard titration starting at 0.25 mg weekly and titrating to 2.4 mg weekly
Treatment: Semaglutide 2.4 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial
- Plain-language title
- Restarting Semaglutide Early After Stomach Surgery in Teens With Severe ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06934655, who can take part
- Record updated
- 2 September 2026